Fig. 3.

Treatment-emergent adverse events per 100 patient-years by years of treatment. AE Adverse event, D/C study discontinuation, IBD inflammatory bowel disease, MACE major adverse cardiovascular events, NMSC non-melanoma skin cancer, p-y patient-years, Rx reaction, SAE serious adverse event